Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,226 stopped studies mapped to Malignant Digestive System Neoplasm and descendants · 91% state a reason
Over the 2,226 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | Phase 1 | terminated | Jan 28, 2020 | Atreca, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | Phase 1 | terminated | Dec 5, 2019 | University of Florida | Sponsor terminated | Other (stated, no rule matched) |
| NCT05514912 | Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without… | Phase 2 | withdrawn | Aug 25, 2022 | Emory University | PI has decided to terminate this study due to study supporter pulling support on this study. | Other (stated, no rule matched) |
| NCT04870034 | Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive… | Early Phase 1 | withdrawn | May 3, 2021 | Roswell Park Cancer Institute | Issues recruiting | Enrollment / accrual |
| NCT05363605 | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | Phase 1 / Phase 2 | terminated | May 6, 2022 | Fusion Pharmaceuticals Inc. | Fusion announced that it is discontinuing this study as part of a portfolio prioritization and… | Sponsor / business decision |
| NCT04097795 | Incremental Cost-Utility Study on Prehabilitation Among Older Patients With Colorectal…(PreColo CU) | — | terminated | Sep 20, 2019 | Radboud University Medical Center | Inclusions lagged far behind | Other (stated, no rule matched) |
| NCT05579444 | Systems Biology of Gastrointestinal and Related Diseases | — | terminated | Oct 13, 2022 | Viome | Lack of enrollment. | Enrollment / accrual |
| NCT03525392 | Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in… | Phase 1 | terminated | May 15, 2018 | Ipsen | Due to agreement to transfer rights for IPN01087 to an external partner, not due to safety concerns | Safety / toxicity |
| NCT02146508 | Endoscopic Prevention of Esophageal Cancer at Tenwek Hospital(EXPECT) | N/A | suspended | May 23, 2014 | Tenwek Hospital | Medtronic owns Covidien \& closed study 11/18/15. Will reapply through Medtronic. | COVID-19 / pandemic |
| NCT05193604 | A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects… | Phase 1 | terminated | Jan 18, 2022 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Terminated due to the adjustment of sponsor's development strategies and pipeline. | Sponsor / business decision |
| NCT02802124 | Carbon Ion Radiotherapy for the Treatment of Chinese Hepatocellular Carcinoma | N/A | terminated | Jun 16, 2016 | Shanghai Proton and Heavy Ion Center | For tumor locates away from GI the planned enrolled patient had been completed, but for tumor… | Enrollment / accrual |
| NCT05184283 | Utilization of MAsS in Patients Undergoing LT for HCC | — | terminated | Jan 11, 2022 | Columbia University | Discontinued by Amra Medical due to funding. | Funding |
| NCT05702385 | Clinical Utility Study for Exo-PDAC | N/A | withdrawn | Jan 27, 2023 | Qure Healthcare, LLC | The study sponsor did not wish to proceed with the study | Other (stated, no rule matched) |
| NCT02017366 | Design of the EFECTS Trial(EFECTS) | N/A | withdrawn | Dec 20, 2013 | University Hospital, Gasthuisberg | adapted protocol with changed outcome measures, changed recruitment number, no submission to… | Enrollment / accrual |
| NCT01897454 | Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable… | Phase 2 | terminated | Jul 12, 2013 | Albert Einstein College of Medicine | Study was terminated due to slower than anticipated accrual | Enrollment / accrual |
| NCT02519140 | Assessing How the Viscosity of Submucosal Gel Injections Helps With Endoscopic Mucosal… | Phase 3 | withdrawn | Aug 10, 2015 | Antonios Likourezos | not stated | Not stated |
| NCT03867370 | Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable… | Phase 1 / Phase 2 | terminated | Mar 8, 2019 | Shanghai Junshi Bioscience Co., Ltd. | Enrollment is over, the study was completed | Enrollment / accrual |
| NCT05641922 | Safety and Effectiveness of BioTraceIO 360 for Planning, Monitoring and Assessment of…(PANORAMA2) | N/A | withdrawn | Dec 8, 2022 | Techsomed Medical Technologies LTD | Withdrawn by Sponsor | Other (stated, no rule matched) |
| NCT04637698 | OH2 Oncolytic Viral Therapy in Pancreatic Cancer | Phase 1 / Phase 2 | terminated | Nov 20, 2020 | Binhui Biopharmaceutical Co., Ltd. | Strategy adjustment | Sponsor / business decision |
| NCT04835987 | Evaluation of the Autonomic Nervous System in Patients Undergoing Esophagectomy for Cancer(PROSNACO) | — | withdrawn | Apr 8, 2021 | Centre Hospitalier Universitaire de Saint Etienne | Due to a lack of staff in the department, no inclusion could be realized. | Other (stated, no rule matched) |
| NCT01690715 | Prognostic Value Related to the Presence of Thrombosis or Portal Vein Invasion in…(HSL2012-06) | — | terminated | Sep 24, 2012 | Hospital Sirio-Libanes | There was recruted subject | Other (stated, no rule matched) |
| NCT04329949 | Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic…(RELIANT) | Phase 3 | terminated | Apr 1, 2020 | Corcept Therapeutics | The independent data monitoring committee found no safety issues, however the observed response… | Safety / toxicity |
| NCT04602117 | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine… | Phase 1 | withdrawn | Oct 26, 2020 | QuantumLeap Healthcare Collaborative | Study withdrawn as scientific interest in pursuing the SYD985+Paclitaxel combination has diminished. | Other (stated, no rule matched) |
| NCT04066491 | Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With… | Phase 2 / Phase 3 | terminated | Aug 26, 2019 | EMD Serono Research & Development Institute, Inc. | Based on a review of data conducted by the Independent Data Monitoring Committee (IDMC), Sponsor… | Sponsor / business decision |
| NCT04565327 | Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal… | Phase 2 | terminated | Sep 25, 2020 | Zhen Wang, MD | Slow accrual | Enrollment / accrual |
| NCT03649321 | Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | terminated | Aug 28, 2018 | University of Texas Southwestern Medical Center | Funding was terminated early because research interests were going in a different direction. | Funding |
| NCT01133990 | FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line… | Phase 1 / Phase 2 | terminated | May 31, 2010 | Eisai Inc. | The study was terminated early as the combination of E7820 and FOLFIRI was deemed to be not… | Efficacy / futility |
| NCT03555149 | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment… | Phase 1 / Phase 2 | terminated | Jun 13, 2018 | Hoffmann-La Roche | The Sponsor made the decision to terminate the study due to start up and recruitment issues caused… | Enrollment / accrual |
| NCT04623515 | Radiation Therapy on Pelvic Floor Disorders in Women(RadPFD) | — | terminated | Nov 10, 2020 | Wake Forest University Health Sciences | IRB closure, slow accrual | Enrollment / accrual |
| NCT05111314 | Comparison of Hepatic Intraarterial Versus Systemic Intravenous 68Ga-PSMA PET/CT for… | Early Phase 1 | withdrawn | Nov 8, 2021 | Mayo Clinic | PI requested | Other (stated, no rule matched) |
| NCT00625586 | Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic… | Phase 2 | terminated | Feb 28, 2008 | MacroGenics | Corporate decision | Other (stated, no rule matched) |
| NCT04854434 | A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab… | Phase 2 | terminated | Apr 22, 2021 | Karyopharm Therapeutics Inc | Sponsor decision | Sponsor / business decision |
| NCT04054752 | Vaccine Response With NT-I7 | Phase 1 | withdrawn | Aug 13, 2019 | National Cancer Institute (NCI) | No subjects enrolled. | Enrollment / accrual |
| NCT04983407 | Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced… | Phase 1 / Phase 2 | terminated | Jul 30, 2021 | Aravive, Inc. | Due to business reasons | Sponsor / business decision |
| NCT01545141 | Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer | Phase 1 / Phase 2 | terminated | Mar 6, 2012 | Roswell Park Cancer Institute | not stated | Not stated |
| NCT01307956 | Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or… | Phase 2 | terminated | Mar 3, 2011 | University of Nebraska | Drug manufacturer - Amgen requested study stop, per DSMB observation in POWER trial | Drug supply |
| NCT04235660 | Y90 Radiation Segmentectomy vs SBRT for HCC(SBRT vs Y90) | N/A | terminated | Jan 22, 2020 | Indiana University | unable to recruit. terminated due to futility | Efficacy / futility |
| NCT06017323 | Proglumide With Gemcitabine and Nab-Paclitaxel in PatientsWith Metastatic Pancreatic…(ProglumidePanc) | Phase 1 | withdrawn | Aug 30, 2023 | Georgetown University | STUDY00006987 | Other (stated, no rule matched) |
| NCT01366833 | Optimal Management of Malignant Dysphagia | N/A | terminated | Jun 6, 2011 | McGill University Health Centre/Research Institute of the McGill University Health Centre | Low accrual | Enrollment / accrual |
| NCT02383433 | Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer | Phase 2 | terminated | Mar 9, 2015 | Case Comprehensive Cancer Center | PI discretion based on low accrual | Enrollment / accrual |
| NCT02626377 | Multicenter Prospective Cohort of Informal Caregivers in Burgundy and Franche-Comté(ICE) | N/A | terminated | Dec 10, 2015 | Centre Hospitalier Universitaire de Besancon | inclusions problems | Other (stated, no rule matched) |
| NCT04977401 | EndoscoPic Submucosal dIssection Using geL Versus glycerOl for Submucosal iNjection(EPSILON) | N/A | terminated | Jul 26, 2021 | Erasme University Hospital | Urgent Medical Device Product (ORISE Gel Submucosal Liftiong Agent) Removal by sponsor | Other (stated, no rule matched) |
| NCT06090318 | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With… | Phase 1 / Phase 2 | withdrawn | Oct 19, 2023 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT03714555 | Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar,… | Phase 2 | terminated | Oct 22, 2018 | HonorHealth Research Institute | Study was closed due to low subject enrollment at site. | Enrollment / accrual |
| NCT03592641 | Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal… | Phase 2 | terminated | Jul 19, 2018 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT03722108 | Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic…(REGIRI) | Phase 1 / Phase 2 | terminated | Oct 26, 2018 | UNICANCER | Unfavorable benefit-risk balance in the experimental arm following the IDMC for intermediate… | Safety / toxicity |
| NCT03490760 | Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas | Phase 2 | terminated | Apr 6, 2018 | Baptist Health South Florida | Slow/poor enrollment | Enrollment / accrual |
| NCT05821582 | Study SBX-01-101: A Stool Collection Study in Colorectal Cancer (CRC) Patients Treated… | — | withdrawn | Apr 20, 2023 | Sanguine Biosciences | Insufficient recruitment population. | Enrollment / accrual |
| NCT02847468 | Multimetabolic 18F-Fluorodeoxyglucose (FDG) and 18F-Fluorocholine (FCH) Positron Emission…(PREMETHEP) | N/A | terminated | Jul 28, 2016 | Centre Georges Francois Leclerc | Insufficient recruitment | Enrollment / accrual |
| NCT03122106 | Neoantigen DNA Vaccine in Pancreatic Cancer Patients Following Surgical Resection and… | Phase 1 | terminated | Apr 20, 2017 | Washington University School of Medicine | Loss of funding | Funding |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Dec 29, 2023source: clinicaltrials